Two overall objectives will be pursued in our continued efforts to treat patients with otherwise fatal? nonmalignant hematologic diseases by allogeneic hematopoietic cell transplantation. One is to reduce? regimen-related toxicities and transplant-related complications, including graft rejection and graft-vs-host? disease. The other is to broaden the choice of hematopoietic cell donors beyond HLA-matched relatives and? unrelated volunteers by including grafts of unrelated cord blood and HLA-haploidentical marrow cells.? Nonmalignant disorders include three distinct disease entities, aplastic anemia. Fanconi anemia, and? inherited diseases of the hematopoietic and immune systems.? In order to assure accrual of patients with these relatively infrequent diseases to the proposed protocols,? we have taken two steps. The first has been to include other academic centers as participants in the? studies. The second, important for protocols involving patients with immunodeficiency diseases, has been to? establish close collaborations with key members of the Pediatric Immunology group at the University of? Washington/Children's Hospital and Regional Medical Center, who see and study many of these patients.? The studies proposed under this Project have relevance for hematopoietic cell transplantation in patients? with hemoglobinopathies, such as sickle cell disease and thalassemia major, autoimmune diseases, and? those with malignant diseases, including myelodysplastic syndromes studied under Project 4 of this grant.? Also, hematopoietic cell transplantation protocols, that are found to be both effective and safe for patients? with hematologic diseases, might eventually be of interest in the treatment of recipients of solid organ grafts,? e.g. kidney or lung. In that setting, a concurrent or preceding hematopoietic graft from the kidney or lung? donor would provide an immunologic """"""""platform"""""""" for the solid organ graft, which would be indefinitely? accepted without the need for lifelong immunosuppression.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL036444-26
Application #
7294710
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2006-08-15
Project End
2011-07-31
Budget Start
2006-08-15
Budget End
2007-07-31
Support Year
26
Fiscal Year
2006
Total Cost
$161,513
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Thakar, M S; Bonfim, C; Walters, M C et al. (2017) Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplant 52:570-573
Burroughs, Lauri M; Shimamura, Akiko; Talano, Julie-An et al. (2017) Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biol Blood Marrow Transplant 23:1669-1677
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Khera, Nandita; Gooley, Ted; Flowers, Mary E D et al. (2016) Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1319-1323
Karoopongse, Ekapun; Marcondes, A Mario; Yeung, Cecilia et al. (2016) Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biol Blood Marrow Transplant 22:1173-1181
Hoffmeister, P A; Storer, B E; Syrjala, K L et al. (2016) Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. Bone Marrow Transplant 51:153-6
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-1233

Showing the most recent 10 out of 788 publications